



Prostate Tumor Marker (YPMA-2): sc-52882

BACKGROUND

Prostate cancer is the ninth most common cancer in the world, and is the number one non-skin cancer that affects men in the United States. Prostate cancer occurs when cells of the prostate mutate and begin to multiply inappropriately. These cells may metastasize from the prostate to other parts of the body, especially the bones, lymph nodes, rectum and bladder. Prostate tumors have unique proteins that may be useful as cancer markers during diagnosis and treatment. A few of the proteins that are specific for prostate tumors include α -methylacyl-CoA racemase (AMACR), the hypermethylated form of retinoic acid receptor β 2 (RAR β 2), and prostate specific antigen (PSA), which is the most reliable clinical tool for diagnosing and monitoring prostate cancer.

REFERENCES

1. Darson, M.F., Pacelli, A., Roche, P., Rittenhouse, H.G., Wolfert, R.L., Young, C.Y., Klee, G.G., Tindall, D.J. and Bostwick, D.G. 1997. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. *Urology* 49: 857-862.
2. Struewing, J.P., Hartge, P., Wacholder, S., Baker, S.M., Berlin, M., McAdams, M., Timmerman, M.M., Brody, L.C. and Tucker, M.A. 1997. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N. Engl. J. Med.* 336: 1401-1408.
3. Sarkar, P., Pal, P.S., Ghosh, D., Setford, S.J. and Tothill, I.E. 2002. Amperometric biosensors for detection of the prostate cancer marker (PSA). *Int. J. Pharm.* 238: 1-9.
4. Miller, D.C., Hafez, K.S., Stewart, A., Montie, J.E. and Wei, J.T. 2003. Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base. *Cancer* 98: 1169-1178.
5. Jerónimo, C., Henrique, R., Hoque, M.O., Ribeiro, F.R., Oliveira, J., Fonseca, D., Teixeira, M.R., Lopes, C. and Sidransky, D. 2004. Quantitative RAR β 2 hypermethylation: a promising prostate cancer marker. *Clin. Cancer Res.* 10: 4010-4014.
6. Jiang, Z., Wu, C.L., Woda, B.A., Iczkowski, K.A., Chu, P.G., Tretiakova, M.S., Young, R.H., Weiss, L.M., Blute, R.D., Brendler, C.B., Krausz, T., Xu, J.C., Rock, K.L., Amin, M.B. and Yang, X.J. 2004. α -methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. *Histopathology* 45: 218-225.
7. Roobol, M.J., Kranse, R., de Koning, H.J. and Schröder, F.H. 2004. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC Rotterdam. *Urology* 63: 309-313.
8. Peyromaure, M. 2005. Pro PSA: a new prostate cancer marker. *Prog. Urol.* 14: 8-11.
9. van der Crujisen-Koeter, I.W., Vis, A.N., Roobol, M.J., Wildhagen, M.F., de Koning, H.J., van der Kwast, T.H. and Schröder, F.H. 2005. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. *J. Urol.* 174: 121-125.

SOURCE

Prostate Tumor Marker (YPMA-2) is a mouse monoclonal antibody raised against PMA of human origin.

PRODUCT

Each vial contains 100 μ g IgG $_3$ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Prostate Tumor Marker (YPMA-2) is recommended for detection of Prostate mucin antigen of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500); non cross-reactive with fetal or benign prostate specimens, non-prostate carcinomas and normal human tissues.

Molecular Weight of Prostate Tumor Marker: 100 kDa.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.